YPSOMED HOLDING AG |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 337.5 CHF | -0.44% |
|
-11.18% | +11.39% |
| Apr. 16 | Ypsomed Partners with ten23 health for Wearable Injector Product Commercialization | MT |
| Apr. 12 | Dental Equipment Company Straumann Names New Chair | MT |
Valuation
| Fiscal Period: March | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 1,607 | 1,575 | 1,999 | 2,061 | 2,626 | 4,606 | - | - |
| Enterprise Value (EV) 1 | 1,717 | 1,746 | 2,191 | 2,311 | 2,758 | 4,819 | 4,892 | 4,911 |
| P/E ratio | 26.7 x | 137 x | 345 x | 89.1 x | 50.4 x | 60.7 x | 43.6 x | 37.3 x |
| Yield | 0.43% | 0.16% | 0.73% | 0.37% | 0.68% | 0.47% | 0.68% | 0.85% |
| Capitalization / Revenue | 3.54 x | 4 x | 4.95 x | 4.43 x | 5.28 x | 8.3 x | 6.97 x | 6.08 x |
| EV / Revenue | 3.78 x | 4.43 x | 5.43 x | 4.97 x | 5.54 x | 8.68 x | 7.41 x | 6.48 x |
| EV / EBITDA | 14.5 x | 28.1 x | 33.6 x | 23.9 x | 19.8 x | 36 x | 27.3 x | 21.4 x |
| EV / FCF | -36.6 x | -63.1 x | 82.2 x | 67.7 x | 90 x | -73.4 x | -1,231 x | 41.5 x |
| FCF Yield | -2.73% | -1.58% | 1.22% | 1.48% | 1.11% | -1.36% | -0.08% | 2.41% |
| Price to Book | 4.26 x | 4.21 x | 5.07 x | 5.25 x | 4.67 x | 7.39 x | 6.56 x | 5.77 x |
| Nbr of stocks (in thousands) | 12,603 | 12,603 | 12,603 | 12,643 | 13,650 | 13,649 | - | - |
| Reference price 2 | 127.5 | 125.0 | 158.6 | 163.0 | 192.4 | 337.5 | 337.5 | 337.5 |
| Announcement Date | 5/23/19 | 5/27/20 | 5/26/21 | 5/25/22 | 5/24/23 | - | - | - |
1CHF in Million2CHF
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: March | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 453.8 | 393.9 | 403.7 | 464.8 | 497.5 | 554.9 | 660.7 | 757.9 |
| EBITDA 1 | 118.2 | 62.09 | 65.29 | 96.66 | 139.2 | 133.7 | 179.5 | 229 |
| EBIT 1 | 73.34 | 9.289 | 9.269 | 28.58 | 60.59 | 77.28 | 119.4 | 143 |
| Operating Margin | 16.16% | 2.36% | 2.3% | 6.15% | 12.18% | 13.93% | 18.07% | 18.87% |
| Earnings before Tax (EBT) 1 | 69.88 | 7.456 | 6.113 | 25.54 | 56.64 | 83 | 95 | 108 |
| Net income 1 | 60.14 | 11.45 | 5.811 | 23.1 | 51.28 | 76.26 | 99.1 | 123.4 |
| Net margin | 13.25% | 2.91% | 1.44% | 4.97% | 10.31% | 13.74% | 15% | 16.29% |
| EPS 2 | 4.770 | 0.9100 | 0.4600 | 1.830 | 3.820 | 5.563 | 7.737 | 9.040 |
| Free Cash Flow 1 | -46.94 | -27.66 | 26.64 | 34.11 | 30.65 | -65.65 | -3.976 | 118.5 |
| FCF margin | -10.35% | -7.02% | 6.6% | 7.34% | 6.16% | -11.83% | -0.6% | 15.63% |
| FCF Conversion (EBITDA) | - | - | 40.81% | 35.29% | 22.03% | - | - | 51.72% |
| FCF Conversion (Net income) | - | - | 458.51% | 147.65% | 59.78% | - | - | 95.97% |
| Dividend per Share 2 | 0.5500 | 0.2000 | 1.160 | 0.6000 | 1.300 | 1.590 | 2.280 | 2.853 |
| Announcement Date | 5/23/19 | 5/27/20 | 5/26/21 | 5/25/22 | 5/24/23 | - | - | - |
1CHF in Million2CHF
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: March | 2020 S1 | 2020 S2 | 2021 S1 | 2021 S2 | 2022 S1 | 2022 S2 | 2023 S1 | 2023 S2 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 190.6 | 203.2 | 199.3 | 204.3 | 222.6 | 242.3 | 244.2 | 253.2 |
| EBITDA 1 | 31.75 | 30.34 | 33.83 | 31.46 | 42.43 | 54.23 | 56.88 | 82.27 |
| EBIT 1 | 9.035 | 0.254 | 8.342 | 0.927 | 10.49 | 18.09 | 19.44 | 41.15 |
| Operating Margin | 4.74% | 0.12% | 4.18% | 0.45% | 4.71% | 7.47% | 7.96% | 16.25% |
| Earnings before Tax (EBT) | - | - | - | - | - | - | - | - |
| Net income 1 | 7.603 | 3.849 | 6.528 | -0.717 | 7.124 | - | 15.44 | 35.84 |
| Net margin | 3.99% | 1.89% | 3.27% | -0.35% | 3.2% | - | 6.32% | 14.15% |
| EPS 2 | 0.6000 | 0.3100 | 0.5200 | -0.0600 | - | - | 1.170 | 2.650 |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 11/5/19 | 5/27/20 | 11/3/20 | 5/26/21 | 11/4/21 | 5/25/22 | 11/16/22 | 5/24/23 |
1CHF in Million2CHF
Estimates
Balance Sheet Analysis
| Fiscal Period: March | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | 110 | 171 | 193 | 250 | 132 | 212 | 286 | 305 |
| Net Cash position 1 | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | 0.9297 x | 2.749 x | 2.95 x | 2.586 x | 0.947 x | 1.589 x | 1.594 x | 1.331 x |
| Free Cash Flow 1 | -46.9 | -27.7 | 26.6 | 34.1 | 30.7 | -65.6 | -3.98 | 118 |
| ROE (net income / shareholders' equity) | 16.7% | 3.04% | 1.5% | - | 10.7% | 6.1% | 7.4% | 8.9% |
| ROA (Net income/ Total Assets) | 11.1% | - | - | - | - | - | - | - |
| Assets 1 | 544 | - | - | - | - | - | - | - |
| Book Value Per Share 2 | 30.00 | 29.70 | 31.30 | 31.00 | 41.20 | 45.70 | 51.50 | 58.50 |
| Cash Flow per Share 2 | 4.750 | 3.900 | 6.810 | 6.790 | 9.650 | 12.20 | 15.10 | 18.40 |
| Capex 1 | 106 | 76.8 | 59.2 | 51.6 | 98.9 | 169 | 216 | 185 |
| Capex / Sales | 23.45% | 19.49% | 14.66% | 11.1% | 19.88% | 30.46% | 32.62% | 24.41% |
| Announcement Date | 5/23/19 | 5/27/20 | 5/26/21 | 5/25/22 | 5/24/23 | - | - | - |
1CHF in Million2CHF
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
337.5
CHF
Average target price
351.3
CHF
Spread / Average Target
+4.10%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +11.39% | 5.04B | |
| -2.31% | 187B | |
| -3.20% | 106B | |
| -5.04% | 66.9B | |
| +0.20% | 49.45B | |
| +17.29% | 48B | |
| +4.06% | 40.84B | |
| +2.07% | 26.48B | |
| +2.36% | 26.25B | |
| +12.96% | 24.62B |
- Stock Market
- Equities
- YPSN Stock
- Financials Ypsomed Holding AG
